Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review evaluates the anti-aging properties of TSG from He shou wu, finding it may protect against age-related diseases through multiple mechanisms, though further research is needed for clinical application.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This article presents a rare case of cicatricial alopecia in a 59-year-old woman after using the epidermal growth factor receptor inhibitor gefitinib.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.

In this study, researchers at Nottingham Children's Renal Unit found that most pediatric patients switching from Prograf to the generic tacrolimus preparation Adoport maintained stable tacrolimus levels and therapeutic effectiveness, supporting Adoport's use as a cost-saving alternative for the NHS.

In this study, teicoplanin significantly improved hair regrowth and follicle size in mice with dihydrotestosterone-induced androgenetic alopecia, suggesting its potential as a treatment option for hair loss due to its ability to enhance cell proliferation and decrease androgen receptor protein levels.

This case report describes a patient with alopecia universalis who had an excellent and persistent response to oral tofacitinib treatment after one year.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

This study found that oral tofacitinib improved disease activity in patients with lichen planopilaris, suggesting it may be a promising treatment option for this condition.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

This case report presented the successful treatment of a patient with alopecia universalis using tofacitinib.

This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.

This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.

In this study, thread-embedding therapy enhanced hair regrowth in C57BL/6 mice by regulating growth factors associated with hair follicle anagen development and promoting cellular proliferation in hair follicles.

TAK-279 effectively reduces psoriasis symptoms and is safe.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This study reported that canine recombinant IFNγ (KT‐100) significantly improved atopic dermatitis symptoms in dogs compared to placebo, and it appeared to be safe during the study period.

In this study, two patients with severe alopecia areata who did not respond well to oral tofacitinib showed more than 50% hair regrowth after a single dose of intramuscular triamcinolone acetonide.

This study evaluated the efficacy and safety of tofacitinib for treating severe alopecia areata in five patients, finding that three responded favorably with mild side effects, supporting its potential use based on existing research.

This study reported that nanoemulsions significantly improved the skin permeability of thiocolchicoside compared to its aqueous solution, suggesting they are effective carriers for its transdermal delivery.

This letter to the editor discusses data from a study on troglitazone for lipodystrophy, noting significant increases in subcutaneous fat without dietary changes.

In this study, tofacitinib treatment for six months significantly reduced hair loss severity in alopecia areata patients.

Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.

Many patients with alopecia areata relapse after stopping tofacitinib.

This study found that GD-23, a dipeptide ligand of TSPO, exhibited an anxiolytic effect in the elevated plus maze test, which was inhibited by selective neurosteroid synthesis inhibitors, suggesting a neurosteroidogenic mechanism.